Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;36(6):1430-1434.
doi: 10.1002/mds.28545. Epub 2021 Feb 26.

Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease

Ioanna Markaki  1   2 , Theodora Ntetsika  1   2 , Kimmo Sorjonen  1 , Per Svenningsson  1   2   3 ; BioPark Study Group
Affiliations

Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease

Ioanna Markaki et al. Mov Disord. 2021 Jun.

Abstract

Background: The interplay between glycemic control and Parkinson's disease (PD) has long been recognized but not fully understood.

Objectives: To investigate the association of glycated hemoglobin (HbA1c) levels with motor and cognitive symptom progression in a prospective PD cohort.

Methods: Of 244 PD patients, 17 had low HbA1c (≤30 mmol/mol), 184 were euglycemic (HbA1c 31-41 mmol/mol), 18 had high HbA1c (HbA1 ≥42 mmol/mol), and 25 had diabetes mellitus (DM). Survival analysis was applied on time until Hoehn and Yahr stage ≥3 (motor outcome) and until mild cognitive impairment.

Results: Low HbA1c (HR 2.7; 95% CI 1.3-6; P = 0.01) as well as high HbA1c (HR 3.6; 95% CI 1.5-8.9; P = 0.005) but not DM were independent predictors of unfavorable motor outcome.

Conclusions: Both high and low HbA1c levels may be associated with motor symptom progression in PD; however, further studies are needed to confirm these findings and increase understanding regarding causality. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: HbA1c; Parkinson's disease; cognition; glycated hemoglobin; motor outcome.

PubMed Disclaimer

Comment in

References

    1. Schwab RS. Progression and prognosis in Parkinson's disease. J Nerv Ment Dis 1960;130:556-566.
    1. Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord 2011;26(12):2253-2259.
    1. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69(17):1688-1695.
    1. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 2019;34(10):1464-1470.
    1. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology 2018;91(2):e139-e142.

Publication types

Substances

LinkOut - more resources